Organon & Co.
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
OGN$13.87+0.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Number · Description | |||
|---|---|---|---|
| 2.1 | Agreement and Plan of Merger, dated as of April 26, 2026, by and among Organon & Co., Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc. and, solely for the purposes of certain Covered Provisions of the Merger Agreement (as defined therein), Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc. and Sun Pharma (Netherlands) B.V. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on April 27, 2026). | ||
| *♦†10.1 · Amendment No. 8 to Development and Commercialization Agreement, dated May 22, 2026, by and between Samsung Bioepsis Co., Ltd. and Organon LLC. | |||
| *♦†10.2 · Amendment No. 9 to Development and Commercialization Agreement, dated May 26, 2026, by and between Samsung Bioepsis Co. Ltd. and Organon LLC. | |||
| *♦†10.3 · Amendment No. 10 to Development and Commercialization Agreement, dated June 2, 2026, by and between Samsung Bioepsis Co., Ltd. and Organon LLC. | |||
| +10.4 | Amended and Restated Organon & Co. 2021 Incentive Stock Plan (incorporated by reference to the Company’s Definitive Proxy Statement on Schedule 14A filed on April 24, 2026). | ||
| *31.1 | — | Certification of Principal Executive Officer (CEO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| *31.2 | — | Certification of Principal Financial Officer (CFO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| **32.1 | — | Section 1350 Certification of Principal Executive Officer (CEO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| **32.2 | — | Section 1350 Certification of Principal Financial Officer (CFO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS | — | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | — | XBRL Taxonomy Extension Schema Document. | |
| 101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | — | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |
| ♦ · Certain confidential information contained in portions of this exhibit, marked by [***] has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because such portions are (i) not material and (ii) are the type of information the registrant customarily and actually treats as private or confidential. | |||
| † · Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished. | |||
| + · Management contract or compensatory plan or arrangement. | |||
| * · Filed herewith. | |||
| ** · Furnished herewith. | |||
-40-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.